Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034

Report Format: PDF+Excel | Report ID: SR112024A8172
Buy Now

Market Overview:

The 7 major relapsed refractory multiple myeloma markets reached a value of US$ 21.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 34.4 Billion by 2034, exhibiting a growth rate (CAGR) of 4.61% during 2024-2034.

Report Attribute
Key Statistics
Base Year  2023
Forecast Years  2024-2034
Historical Years 
2018-2023
Market Size in 2023
US$ 21.0 Billion
Market Forecast in 2034
US$ 34.4 Billion
Market Growth Rate 2024-2034
4.61%


The relapsed refractory multiple myeloma market has been comprehensively analyzed in IMARC's new report titled "Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Relapsed refractory multiple myeloma, also known as RRMM, is a type of tumor that affects plasma cells, a form of white blood cell found in the bone marrow. This condition refers to a specific stage of the disease where the cancer has returned after a period of initial therapy and has become resistant to further treatment attempts. It is characterized by the presence of worsening symptoms, such as bone pain, fatigue, anemia, kidney problems, weakness, weight loss, lack of appetite, an increase in abnormal plasma cells in the bone marrow or other parts of the body, etc. An individual suffering from this illness may also experience recurrent infections, numbness in the limbs, difficulty with balance and coordination, changes in mental function, excessive thirst, nausea, confusion, constipation, etc. The diagnosis of RRMM is mainly based on a combination of medical history review, clinical feature assessment, and physical examination. Several imaging techniques, like X-rays, CT scans, MRIs, etc., are also utilized to identify the extent of the disease among patients. The healthcare provider may further perform a bone marrow biopsy to determine the presence and characteristics of cancerous plasma cells.

Relapsed Refractory Multiple Myeloma Market

The increasing cases of genetic abnormalities, including chromosomal rearrangements and mutations in specific genes that can contribute to treatment resistance and disease recurrence, are primarily driving the relapsed refractory multiple myeloma market. In addition to this, the rising prevalence of immune dysregulation, which blocks the function of T cells due to alterations in cytokine levels, is also creating a positive outlook for the market. Moreover, the widespread adoption of proteasome inhibitors, such as bortezomib, carfilzomib, ixazomib, etc., to selectively target and destroy the protein metabolism of abnormal plasma cells is further bolstering the market growth. Apart from this, the inflating application of antibody-drug conjugates that combine a monoclonal antibody with a potent anti-cancer drug to enhance the overall treatment response, thereby potentially leading to better outcomes for patients, is acting as another significant growth-inducing factor. Additionally, the escalating popularity of chimeric antigen receptor T-cell (CAR-T) therapy on account of its various advantages, including targeted treatment, long-term disease control, and improved efficacy, is expected to drive the relapsed refractory multiple myeloma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the relapsed refractory multiple myeloma market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for relapsed refractory multiple myeloma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the relapsed refractory multiple myeloma market in any manner.

Time Period of the Study

  • Base Year: 2023
  • Historical Period: 2018-2023
  • Market Forecast: 2024-2034
     

Countries Covered

  • United States
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Japan
     

Analysis Covered Across Each Country

  • Historical, current, and future epidemiology scenario
  • Historical, current, and future performance of the relapsed refractory multiple myeloma market
  • Historical, current, and future performance of various therapeutic categories in the market
  • Sales of various drugs across the relapsed refractory multiple myeloma market
  • Reimbursement scenario in the market
  • In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current relapsed refractory multiple myeloma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     

Late-Stage Pipeline Drugs

  • Drug Overview
  • Mechanism of Action
  • Regulatory Status
  • Clinical Trial Results
  • Drug Uptake and Market Performance
     
Drugs Company Name
Carvykti (Ciltacabtagene autoleucel) Janssen Biotech/Nanjing Legend Biotech
Abecma (Idecabtagene vicleucel) 2seventy bio
Tecvayli (Teclistamab) Genmab/Janssen Research & Development
Xpovio (Selinexor) Karyopharm Therapeutics
Blenrep (Belantamab mafodotin) GlaxoSmithKline
CART-ddBCMA Arcellx
Modakafusp alfa Takeda/Teva Pharmaceutical Industries
Venetoclax AbbVie/Genentech
ISB 1442 Ichnos Sciences
ABBV453 AbbVie


*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

  • How has the relapsed refractory multiple myeloma market performed so far and how will it perform in the coming years?
  • What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
  • What was the country-wise size of the relapsed refractory multiple myeloma market across the seven major markets in 2023 and what will it look like in 2034?
  • What is the growth rate of the relapsed refractory multiple myeloma market across the seven major markets and what will be the expected growth over the next ten years?
  • What are the key unmet needs in the market?
     

Epidemiology Insights

  • What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma by age across the seven major markets?
  • What is the number of prevalent cases (2018-2034) of relapsed refractory multiple myeloma by gender across the seven major markets?
  • How many patients are diagnosed (2018-2034) with relapsed refractory multiple myeloma across the seven major markets?
  • What is the size of the relapsed refractory multiple myeloma patient pool (2018-2023) across the seven major markets?
  • What would be the forecasted patient pool (2024-2034) across the seven major markets?
  • What are the key factors driving the epidemiological trend of relapsed refractory multiple myeloma?
  • What will be the growth rate of patients across the seven major markets?
     

Relapsed Refractory Multiple Myeloma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

  • What are the current marketed drugs and what are their market performance?
  • What are the key pipeline drugs and how are they expected to perform in the coming years?
  • How safe are the current marketed drugs and what are their efficacies?
  • How safe are the late-stage pipeline drugs and what are their efficacies?
  • What are the current treatment guidelines for relapsed refractory multiple myeloma drugs across the seven major markets?
  • Who are the key companies in the market and what are their market shares?
  • What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the relapsed refractory multiple myeloma market?
  • What are the key regulatory events related to the relapsed refractory multiple myeloma market?
  • What is the structure of clinical trial landscape by status related to the relapsed refractory multiple myeloma market?
  • What is the structure of clinical trial landscape by phase related to the relapsed refractory multiple myeloma market?
  • What is the structure of clinical trial landscape by route of administration related to the relapsed refractory multiple myeloma market?

Need more help?

  • Speak to our experienced analysts for insights on the current market scenarios.
  • Include additional segments and countries to customize the report as per your requirement.
  • Gain an unparalleled competitive advantage in your domain by understanding how to utilize the report and positively impacting your operations and revenue.
  • For further assistance, please connect with our analysts.
Relapsed Refractory Multiple Myeloma Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
Purchase options




Benefits of Customization

Personalize this research

Triangulate with your data

Get data as per your format and definition

Gain a deeper dive into a specific application, geography, customer, or competitor

Any level of personalization

Get in Touch With Us
UNITED STATES

Phone: +1-631-791-1145

INDIA

Phone: +91-120-433-0800

UNITED KINGDOM

Phone: +44-753-713-2163

Email: sales@imarcgroup.com

Client Testimonials

Aktive Services

IMARC made the whole process easy. Everyone I spoke with via email was polite, easy to deal with, kept their promises regarding delivery timelines and were solutions focused. From my first contact, I was grateful for the professionalism shown by the whole IMARC team. I recommend IMARC to all that need timely, affordable information and advice. My experience with IMARC was excellent and I can not fault it.

Read More
Greenfish S.A.

The IMARC team was very reactive and flexible with regard to our requests. A very good overall experience. We are happy with the work that IMARC has provided, very complete and detailed. It has contributed to our business needs and provided the market visibility that we required

Read More
Colruyt Group

We were very happy with the collaboration between IMARC and Colruyt. Not only were your prices competitive, IMARC was also pretty fast in understanding the scope and our needs for this project. Even though it was not an easy task, performing a market research during the COVID-19 pandemic, you were able to get us the necessary information we needed. The IMARC team was very easy to work with and they showed us that it would go the extra mile if we needed anything extra

Read More
KRISHAK BHARTI CO-OP LTD

Last project executed by your team was as per our expectations. We also would like to associate for more assignments this year. Kudos to your team.

Read More
Zee Media Corp. Ltd.

We would be happy to reach out to IMARC again, if we need Market Research/Consulting/Consumer Research or any associated service. Overall experience was good, and the data points were quite helpful.

Read More
Arabian Plastic Manufacturing Company Ltd.

The figures of market study were very close to our assumed figures. The presentation of the study was neat and easy to analyse. The requested details of the study were fulfilled. My overall experience with the IMARC Team was satisfactory.

Read More
Sumitomo Corporation

The overall cost of the services were within our expectations. I was happy to have good communications in a timely manner. It was a great and quick way to have the information I needed.

Read More
Hameln Rds

My questions and concerns were answered in a satisfied way. The costs of the services were within our expectations. My overall experience with the IMARC Team was very good.

Read More
Quality Consultants BV

I agree the report was timely delivered, meeting the key objectives of the engagement. We had some discussion on the contents, adjustments were made fast and accurate. The response time was minimum in each case. Very good. You have a satisfied customer.

Read More
TATA Advanced Systems Limited

We would be happy to reach out to IMARC for more market reports in the future. The response from the account sales manager was very good. I appreciate the timely follow ups and post purchase support from the team. My overall experience with IMARC was good.

Read More
Stax

IMARC was a good solution for the data points that we really needed and couldn't find elsewhere. The team was easy to work, quick to respond, and flexible to our customization requests.

Read More